Pascale Augé

Direttore/Membro del Consiglio presso

Laboratoire Français du Fractionnement et des Biotechnologies

55 anni

44 relazioni

Finance

Commercial Services

Health Technology

Profilo

Pascale Augé currently works at Laboratoire Français du Fractionnement et des Biotechnologies, as Director, INSERM Transfert Initiative SAS, as Director, Linkinvax SA, as Director, and eureKING SA, as Independent Director from 2022.
Dr. Augé also formerly worked at INSERM Transfert SA, as Chairman-Management Board from 2014 to 2025, Ernst & Young Audit SAS (France), as Senior Manager from 2004 to 2011, AB Science SA, as Project Manager from 2003 to 2004, and Novachim SA, as Project Manager.

Posizioni attive di Pascale Augé

Società	Posizione	Inizio
Laboratoire Français du Fractionnement et des Biotechnologies Laboratoire Français du Fractionnement et des Biotechnologies Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets plasma-derived medicinal products & recombinant proteins for the treatment of patients	Direttore/Membro del Consiglio	-
Linkinvax SA Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company to develops disrupt vaccine using a unique dendritic cell-targeting vaccine platform	Direttore/Membro del Consiglio	-
eureKING SA eureKING SA Financial ConglomeratesFinance Operates as a special purpose acquisition company	Direttore/Membro del Consiglio	05/05/2022
INSERM Transfert Initiative SAS INSERM Transfert Initiative SAS Investment ManagersFinance Acts as Venture Capital Fund	Direttore/Membro del Consiglio	-

Tutte le posizioni attive di Pascale Augé

Precedenti posizioni note di Pascale Augé

Società	Posizione	Fine
INSERM Transfert SA INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions.	Amministratore Delegato	05/09/2025
Ernst & Young Audit SAS (France) Ernst & Young Audit SAS (France) Miscellaneous Commercial ServicesCommercial Services Provides Auditing & Accounting Services	Corporate Officer/Principal	01/01/2011
AB SCIENCE	Corporate Officer/Principal	01/01/2004
Novachim SA	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Pascale Augé

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Vedi nel dettaglio l'esperienza di Pascale Augé

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	8
INSERM Transfert SA INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions.	Finance
Ernst & Young Audit SAS (France) Ernst & Young Audit SAS (France) Miscellaneous Commercial ServicesCommercial Services Provides Auditing & Accounting Services	Commercial Services
Laboratoire Français du Fractionnement et des Biotechnologies Laboratoire Français du Fractionnement et des Biotechnologies Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets plasma-derived medicinal products & recombinant proteins for the treatment of patients	Health Technology
INSERM Transfert Initiative SAS INSERM Transfert Initiative SAS Investment ManagersFinance Acts as Venture Capital Fund	Finance
AB Science SA AB Science SA Pharmaceuticals: OtherHealth Technology Provides biochemical research services	Health Technology
Linkinvax SA Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company to develops disrupt vaccine using a unique dendritic cell-targeting vaccine platform	Commercial Services
eureKING SA eureKING SA Financial ConglomeratesFinance Operates as a special purpose acquisition company	Finance
Novachim SA